Poly‐lymphomatous Syndrome With Concurrent or Sequential Hodgkin and Non‐Hodgkin lymphoma

Madiha Iqbal, Liuyan Jiang, Ke David Li, Muhamad Alhaj Moustafa, Erin Marie O. Kimbrough, Stephen M. Ansell, Han W. Tun

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The development of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) concurrently or sequentially in the same patient is a rare clinical scenario and can be labeled as a poly-lymphomatous syndrome (PLS). Methods: We report clinico-pathologic characteristics and survival outcomes of 7 such cases from our institution. In concurrent PLS, HL is present with NHL in the same location (composite PLS) or in separate locations (discordant PLS). Sequential presentations were seen with HL following NHL or vice versa (sequential PLS). Conclusions: It is essential to perform adequate biopsies in supposedly relapsed or refractory settings to diagnose PLS. We suggest that the incidence of PLS is likely underestimated due to the under-utilization of repeat biopsies. In patients with concurrent PLS, the treatment should ideally cover both types of lymphoma with an emphasis on tailoring the treatment towards the more aggressive lymphoma. In patients with sequential PLS, the treatment should target the new lymphoma. Consolidation treatments such as autologous hematopoietic cell transplant should be considered when there is a component of relapsed cHL or aggressive NHL. Based on our experience, PLS does not appear to be associated with a poor prognosis. Further research is necessary for better understanding of the biology and management of PLS.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - 2022

Keywords

  • Concurrent
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Poly-lymphomatous syndrome
  • Sequential

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Poly‐lymphomatous Syndrome With Concurrent or Sequential Hodgkin and Non‐Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this